• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

February 2, 2020
Company Drug/Device Medical Condition Status
ORIC Pharmaceuticals ORIC-101 in combination with XTANDI (enzalutamide) metastic prostate cancer phase 1b trial dosing first patient
Syros Pharmaceuticals SY-5609 select solid tumors phase 1 trial dosing first patient
Ikena Oncology IK-175 (formerly KYN-175) advanced solid tumors phase 1 trial dosing first patient
Rubius Therapeutics RTX-134 phenylketonuria phase 1b trial dosing first patient
Cerevel Therapeutics CVL-936 substance use disorder phase 1 trial initiated
GlycoMimetics GMI-1359 advanced breast cancer phase 1b trial dosing first patient
Epygenix Therapeutics EPX-100 Dravet Syndrome phase 1 trial completed
Hansa Biopharma imlifidase Anti-GBM antibody disease phase 2 investigator-initiated trial enrolling 15 patients
Anavex Life Sciences ANAVEX 2-73 (blarcamesine) Parkinson’s Disease phase 2 trial enrolling 120 patients at 20 sites across Spain and three sites in Australia
Cassava Sciences PTI-125 Alzheimer’s Disease phase 2b trial enrolling 64 patients
Isofol Medical arfolitixorin metastatic colorectal cancer phase 1/2 trial completed
VistaGen Therapeutics AV-101 oral NMDAR (N-methyl-D-aspartate receptor) dyskinesia in patients with Parkinson's Disease receiving levodopa-based therapy phase 2 IND cleared by the FDA
NuCana Acelarin (NUC-1031) biliary tract cancer phase 3 trial dosing first patients in U.S. and Europe
Abbott Infinity Deep Brain Stimulation system Parkinson’s Disease approved by the FDA for new indication
Epizyme Tezverik (tazemetostat) metastatic or locally advanced epithelioid sarcoma not eligible for complete resection approved by the FDA
Merck Dificid (fidaxomicin) Clostridioides difficile-associated diarrhea in children ages six months and older approved by the FDA
Teva Pharmaceuticals USA AJOVY (fremanezumab-vfrm) autoinjector migraine approved by the FDA
Boehringer Ingelheim

Eli Lilly
Trijardy XR type 2 diabetes approved by the FDA
Pharmacosmos Therapeutics Monoferric (ferric derisomaltose) injection iron deficiency anemia approved by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing